03 November 2021 | News
Open to all COVID-19 vaccine developers, CEPI’s centralised labs network seeks to minimise variation in assessment of COVID-19 vaccine candidates
image credit- CEPI
Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) and Q2 Solutions, a wholly owned subsidiary of IQVIA and a leading clinical trial laboratory services organisation, have announced that Q2 Solutions’ facility in Beijing, China, has joined CEPI’s centralised laboratory network.
This network is the largest and only global group launched to harmonise the assessment of COVID-19 vaccines currently undergoing preclinical and clinical trials.
Q2 Solutions (Beijing) Co., Ltd. becomes the eleventh laboratory to join the network, and the first in East Asia.
The sample testing facility will follow the other CEPI-supported laboratories, all using the same methodologies and key reagents—substances used to carry out a scientific test—to measure and compare the type of immune responses and magnitude that the COVID-19 vaccines under development generates over time.
This is in contrast to the typical vaccine evaluation process, where the immune response of a vaccine candidate is assessed using different tools and measurements at individual testing sites, allowing for inter-laboratory variability. Following a centralised approach standardises testing of COVID-19 vaccines to ensure uniformity in assessment and allows researchers and regulators to accurately identify the most promising candidates.